Structured evidence table for Vitamin K2 Vascular Calcification Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Vitamin K2 Vascular Calcification Randomized Trial | Once dismissed as a result of passive leaflet degeneration, the pathophysiology of AS is now considered an intricate process orchestrated by immune activation, oxidative injury, lipid infiltration, and metabolic dysregulation [,,]. | 3 | Moroz Simina Mariana (2026) | Metabolic Drivers of Valve Calcification and Atrial Remodeling in Calcific Aortic Stenosis |
| Vitamin K2 Vascular Calcification Randomized Trial | Clinically, AS is associated not only with valvular obstruction but also with profound structural and electrical remodeling of the left ventricle and atria—manifesting as hypertrophy, fibrosis, diastolic dysfunction, and atrial fibrillation (AF) [,,,]. | 3 | Moroz Simina Mariana (2026) | Metabolic Drivers of Valve Calcification and Atrial Remodeling in Calcific Aortic Stenosis |
| Vitamin K2 Vascular Calcification Randomized Trial | With increasing life expectancy and improved management of coronary artery disease, the burden of AS is rising globally [,,]. | 3 | Moroz Simina Mariana (2026) | Metabolic Drivers of Valve Calcification and Atrial Remodeling in Calcific Aortic Stenosis |
| Vitamin K2 Vascular Calcification Randomized Trial | 1 2 3 1 4 5 2 3 6 7 6 7 8 1 2 4 1 2 4 1 4 9 10 11 12 13 14 6 7 15 16 6 7 15 16 17 Aortic stenosis (AS) affects a significant proportion of the elderly population, particularly individuals over 75 years [,,]. | 3 | Moroz Simina Mariana (2026) | Metabolic Drivers of Valve Calcification and Atrial Remodeling in Calcific Aortic Stenosis |
Source documents